Coping and risk perception during the COVID-19 pandemic in type 2 diabetes: Does it influence metabolic control?

Diabetes and poor glycemic control are significant predictors of severity and death in the COVID-19 disease. The perception of this risk in individuals with type 2 diabetes (T2D) could modify coping styles, leading to behaviors associated with better self-care and metabolic control. Theoretically, active coping is associated with better glycemic control in patients with T2D. Nonetheless, information during extreme risk like the COVID-19 pandemic is still limited. Our objective was to evaluate the association between coping styles and risk perception in the COVID-19 pandemic and the change in metabolic parameters. This is a prospective study that included individuals with T2D treated in a tertiary care center during the COVID-19 outbreak who returned to follow-up one year later. We assessed coping styles and risk perception with the Extreme Risk Coping Scale and the risk perception questionnaire. Clinical characteristics and metabolic parameters were registered in both visits. Groups were compared using Kruskal Wallis tests, and changes in metabolic parameters were assessed with Wilcoxon rank sum tests. Our sample included 177 participants at baseline, and 118 concluded the study. Passive coping was more frequent in women. Low-risk perception was associated with higher age, lower psychiatric comorbidities, and lower frequency of psychiatric treatment compared with other risk perception groups. Patients with active coping plus high-risk perception did not have a change in metabolic parameters at follow-up, whereas patients with other coping styles and lower risk perception had an increase in total cholesterol, LDL-cholesterol, and triglycerides. There were no differences by coping group or by risk perception in glycemic control.

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.

Prognostic impact of non-MPN driver gene mutations in primary myelofibrosis. MIPSS70: Mutation-Enhanced International Prognostic Score System.

Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.

To elucidate the role of splanchnic vein thrombosis (SVT) and genomic characteristics in prognosis and survival, we compared patients with polycythemia vera (PV) or essential thrombocythemia (ET) presenting SVT at diagnosis (n = 69, median age 43 years) or during follow-up (n = 21, median age 46 years) to a sex- and age-matched control group of PV/ET without SVT (n = 165, median age 48 years). The majority of patients presenting with SVT at diagnosis were classified as myeloproliferative neoplasm with heterozygous JAK2 mutation (87% of cases vs. 69% in PV/ET control group, p < 0.05), characterized by low JAK2 allele burden and no high-risk mutations. Despite this lower molecular complexity, patients presenting with SVT showed a higher risk of death (HR 3.0, 95% CI 1.5-6.0, p = 0.003) and lower event-free survival (HR 3.0, 95% CI 1.9-4.8, p < 0.001) than age- and sex-matched PV/ET controls. In patients presenting with SVT, molecular high-risk was associated with increased risk of venous re-thrombosis (HR 5.8, 95% CI 1.4-24.0, p = 0.01). Patients developing SVT during follow-up were more frequently allocated in molecular high-risk than those with SVT at diagnosis (52% versus 13%, p < 0.05). In the whole cohort of patients, molecular classification identified PV/ET patients at higher risk of disease progression whereas DNMT3A/TET2/ASXL1 mutations were associated with higher risk of arterial thrombosis. In conclusion, clinical and molecular characteristics are different in PV/ET patients with SVT, depending on whether it occurs at diagnosis or at follow-up. Molecular characterization by NGS is useful for assessing the risk of thrombosis and disease progression in young patients with PV/ET.

Electrochemical Synthesis of S-Aryl Dibenzothiophenium Triflates as Precursors for Selective Nucleophilic Aromatic (Radio)fluorination.

A novel electrosynthetic approach to aryl dibenzothiophenium salts, including the direct intramolecular formation of a C-S bond in a metal-free, electrochemical key step under ambient conditions, is reported. The broad applicability of this method is demonstrated with 14 examples, including nitrogen-containing heterocycles in isolated yields up to 72%. The resulting sulfonium salts can be used as precursors for fluorine labeling to give [18F]fluoroarenes as found in PET tracer ligands.

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.

Myelofibrosis (MF) is a heterogeneous disease regarding its mutational landscape, clinical presentation, and outcomes. The aim of our work is to evaluate the genomic classification of MF considering whether it is primary or secondary. One-hundred seventy-five patients, 81 with primary MF (PMF) and 94 with secondary MF (SMF) were hierarchically allocated into eight molecular groups. We found that TP53 disruption/aneuploidy (n = 16, 9%) was more frequent (12% versus 6%) and showed higher allele burden (57% versus 15%, p = 0.01) in SMF than in PMF, and was associated with shorter survival (median 3.5 years). Mutations in chromatin/spliceosome genes (n = 72, 41%) represented the most frequent genomic group in PMF. Homozygous JAK2 mutation (n = 40, 23%) was enriched with old patients with SMF after long-standing polycythemia vera, whereas MF with heterozygous JAK2 mutation (n = 22, 13%) was similarly distributed among PMF and SMF. MF with CALR mutation (n = 19, 11%) predominated in post-essential thrombocythemia MF. The remaining genomic groups were infrequent. TP53 disruption, chromatin/spliceosome mutation, and homozygous JAK2 mutation were associated with significantly shorter survival and higher risk of progression. In conclusion, genomic classification reveals different pathogenic pathways between PMF and SMF and provides relevant information regarding disease phenotype and outcomes.

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.

The International Prognostic Score of thrombosis in Essential Thrombocythemia (IPSET-thrombosis) and its revised version have been proposed to guide thrombosis prevention strategies. We evaluated both classifications to prognosticate thrombosis in 1366 contemporary essential thrombocythemia (ET) patients prospectively followed from the Spanish Registry of ET. The cumulative incidence of thrombosis at 10 years, taking death as a competing risk, was 11.4%. The risk of thrombosis was significantly higher in the high-risk IPSET-thrombosis and high-risk revised IPSET-thrombosis, but no differences were observed among the lower risk categories. Patients allocated in high-risk IPSET-thrombosis (subdistribution hazard ratios [SHR], 3.7 [95% confidence interval, CI, 1.6-8.7]) and high-risk revised IPSET-thrombosis (SHR, 3.2 [95% CI, 1.4-7.45]) showed an increased risk of arterial thrombosis, whereas both scoring systems failed to predict venous thrombosis. The incidence rate of thrombosis in intermediate risk revised IPSET-thrombosis (aged >60 years, JAK2-negative, and no history of thrombosis) was very low regardless of the treatment administered (0.9% and 0% per year with and without cytoreduction, respectively). Dynamic application of the revised IPSET-thrombosis showed a low rate of thrombosis when patients without history of prior thrombosis switched to a higher risk category after reaching 60 years of age. In conclusion, IPSET-thrombosis scores are useful for identifying patients at high risk of arterial thrombosis, whereas they fail to predict venous thrombosis. Controlled studies are needed to determine the appropriate treatment of ET patients assigned to the non-high-risk categories.

Long-Term Effects of Anxiety on the Metabolic Control of Recently Diagnosed Type 2 Diabetes Patients: Results from the CAIPaDi Cohort Study.

Introduction: Anxiety disorders (AXD) are among the most prevalent mental health conditions in patients with type 2 diabetes (T2D). Previous data have established an association of other psychiatric conditions with poor metabolic control and increased odds of diabetes-related complications. Nonetheless, follow-up information about the effects of AXD on the metabolic control of patients with TD2 is still limited. Objective: Evaluate the effects of AXD on the metabolic parameters of patients with T2D over 12 months of follow-up in a multidisciplinary comprehensive care model. Methods: Prospective study of T2D subjects enrolled in a comprehensive care program with follow-up at 3 and 12 months of treatment. Patients were assessed using the Mini-International Neuropsychiatric Interview and the Hospital Anxiety and Depression Scale (HADS). We registered clinical and metabolic characteristics from each visit. Metabolic parameters over time were analyzed with a mixed model of repeated measures using AXD and time as interaction variables. Results: Our sample included 2703 patients at baseline, and 1161 (43%) subjects continued the follow-up at 12 months. The AXD group had more females, lower age, and fewer years of formal education compared with subjects without AXD at baseline, 3 and 12 months. Patients with AXD also reported higher mean fasting glucose at three months, and higher HbA1c at three and 12 months. Our MMRM for HbA1c reported significant differences over time in subjects with and without AXD. The differences in means between groups increased from 0.17% at three months to 0.31% at 12 months. The variables from the HADS anxiety score, sex, age, years of diagnosis, and insulin treatment were also associated with HbA1c parameters over time. Conclusion: Patients with AXD had the worst glycemic control at 3 and 12 months of follow-up. HbA1c differences in patients with AXD compared with non-AXD subjects increases over time in association with anxiety symptoms.

Un caso de paracoccidioidomicosis en laglándula suprarrenal bilateral / A case of paracoccidioidomycosisin the bilateral adrenal gland

La paracoccidioidomicosis es una micosis profunda. La afectación de la glándula suprarrenal es una forma de presentación rara que se asocia hasta un 10 a 15% de las insuficiencias supra renales y en algunas ocasiones puede ser la primera manifestación clínica de la patología. El objetivo del estudio es describir una presentación atípica de un paciente con diagnóstico de tumoración bilateral de la glándula supra renal, que en primer lugar se sospechó de un proceso tumoral de las glándulas supra renales y con la biopsia con punción guiada por ecografía se llegó al diagnóstico definitivo de paracocciodioidomicosis suprarrenal. Se realiza tratamiento con anfotericina B a una dosis de 50mg/día hasta una dosis acumulativa de 1500mg, con posterior seguimiento con itraconazol de 200 a 400mg/día por un periodo de 6 a 12 meses. Palabras Clave: paracoccidioidomicosis; glándulas suprarrenales; infecciones fúngicas invasoras

Paracoccidioidomycosis is aninvasive fungal infection.Involvement of the adrenal gland isa rare form of presentation that is associated with up to 10 to 15% of suprarenal insufficiencies and sometimes it can be the first clinical manifestation of the pathology. The objective of the study is to describean atypical presentation of a patient with a diagnosis of bilateral tumor of the suprarenal gland, that was suspected of a tumor process of the suprarenal glands and the definitive diagnosis with ultrasound-guided puncture biopsy was adrenal paracocciodioidomycosis.Treatment is carried out with amphotericin B at a dose of 50 mg/day up to a cumulative dose of 1500 mg, with subsequent follow-up with itraconazole of 200 to 400 mg/day for a period of 6 to 12 months. Key Words: paracoccidioidomycosis; adrenal glands; invasive fungal infections

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication is critical for treatment decision-making. We obtained registry data from patients diagnosed with MF in 60 Spanish institutions (N = 1386). These were randomly divided into a training set (80%) and a test set (20%). A machine learning (ML) technique (random forest) was used to model overall survival (OS) and leukemia-free survival (LFS) in the training set, and the results were validated in the test set. We derived the AIPSS-MF (Artificial Intelligence Prognostic Scoring System for Myelofibrosis) model, which was based on 8 clinical variables at diagnosis and achieved high accuracy in predicting OS (training set c-index, 0.750; test set c-index, 0.744) and LFS (training set c-index, 0.697; test set c-index, 0.703). No improvement was obtained with the inclusion of MPN driver mutations in the model. We were unable to adequately assess the potential benefit of including adverse cytogenetics or high-risk mutations due to the lack of these data in many patients. AIPSS-MF was superior to the IPSS regardless of MF subtype and age range and outperformed the MYSEC-PM in patients with secondary MF. In conclusion, we have developed a prediction model based exclusively on clinical variables that provides individualized prognostic estimates in patients with primary and secondary MF. The use of AIPSS-MF in combination with predictive models that incorporate genetic information may improve disease risk stratification.

Factores asociados y propiedades psicométricas de la versión en español del Test Breve de Irritabilidad (BITe) en población paraguaya / Associated factors and psychometric properties of the Spanish version of the Brief Irritability Test (BITe) in Paraguayan population

Antecedentes: La irritabilidad, como síntoma transdimensional, está presente en varios trastornos mentales. Este estudio investigó las propiedades psicométricas de la versión española del Test Breve de Irritabilidad (BITe). Sujetos y métodos: el reclutamiento se realizó a través de una encuesta en línea lanzada a través de las redes sociales comunes (Facebook, Twitter) y aplicaciones de mensajería (WhatsApp, Telegram) del 1 al 31 de mayo de 2022. Los sujetos incluidos fueron personas ≥ 18 años de edad de ambos sexos 1920 individuos fueron calificados para el analisis de validacion. El BITe ha sido traducido al español y validado mediante análisis factorial confirmatorio. Los participantes también han sido puntuados con el Cuestionario de Agresión (AQ). Resultados: la prueba de Kaiser-Meyer-Olkin (KMO) fue adecuada (KMO=0,880) y la esfericidad se probó significativamente (p<0,001). El análisis confirmatorio que garantiza que la escala es unidimensional. El ajuste del modelo fue bueno, según todos los índices de ajuste. El alfa de Cronbach también garantiza una excelente consistencia interna (α=0,91). Las calculadoras entre las dos escalas (BITe y AQ) han mostrado una buena convergencia (r=0,512; p<0,001). Conclusiones: La versión en español del BITe es una escala unidimensional de cinco elementos tipo Likert que muestra buena validez interna y alta confiabilidad, lo que implica que esta versión tiene excelentes propiedades psicométricas tanto para hombres como para mujeres hispanohablantes.

Background: Irritability, as a trans dimensional symptom, is present in several mental disorders.This study investigated the psychometric properties of the Spanish version of the Brief Irritability Test (BITe). Subjects and Methods: The recruitment has been performed through an online survey launched through common social media (Facebook, Twitter) and messaging apps (WhatsApp, Telegram) from 1st to 31st May 2022. Subjects included were individuals ≥18 years old of age of both sexes. 1920 individuals were rated for the validation analysis. The BITe has been translated into Spanish and validated through confirmatory factor analysis. Participants have been also scored with the Aggression Questionnaire (AQ). Results: Kaiser-Meyer-Olkin (KMO) test was adequate (KMO=0.880) and sphericity tested significantly (p<0.001). The confirmatory analysis confirmed that the scale is one- imensional. The model adjustment was good, according to all fit indices. Cronbach's alpha also confirmed an excellent internal consistency (α=0.91). Scores between the two scales (the BITe and the AQ) have shown a good convergence (r=0.512; p<0.001). Conclusions: The Spanish version of the BITe is a unidimensional scale of five Likerttype items that shows good internal validity and high reliability, which implies that this version has excellent psychometric properties for both male and female Spanish-speakers

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.

Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in 1613 patients from the Spanish Myelofibrosis Registry. Over a total of 6981 patient-years at risk, 6.4% of the study population had at least one thrombotic event after MF diagnosis, amounting to an incidence rate of 1.65 per 100 patient-years. Prior history of thrombosis, the JAK2 mutation, and the intermediate-2/high-risk International Prognostic Scoring System (IPSS) categories conferred an increased thrombotic risk after adjustment for the risk-modifying effect of anti-thrombotic and cytoreductive treatments. History of thrombosis and the JAK2 mutation allowed us to pinpoint a group of patients at higher risk of early thrombosis. No decreased incidence of thrombosis was observed while patients were on anti-thrombotic or cytoreductive treatment. An increased risk of venous thrombosis was found during treatment with immunomodulatory agents. A total of 5.3% of patients had at least one episode of major bleeding, resulting in an incidence rate of 1.5 events per 100 patient-years. Patients in the intermediate-2/high-risk IPSS categories treated with anti-coagulants had an almost sevenfold increased risk of major bleeding. These findings should prove useful for guiding decision-making in clinical practice.

Light availability in the cultivation environment and the action of glyphosate on Digitaria insularis: physiological aspects and herbicide root exudation.

The root exudation decreases the susceptibility of some species to herbicides, which is still little studied in Digitaria insularis, popularly known as sourgrass, one of the main weeds of annual crops in the world. Thus, we sought to identify whether there is an occurrence of root exudation of glyphosate in D. insularis and the influence of this herbicide on physiological and control parameters of this species when cultivated under different light conditions. The experimental design was 2 x 5, with the first factor represented by environments: full sun and artificial shading. The second factor was represented by doses 0, 370, 740, 1110, and 1480 g ha-1 of glyphosate. The plants grown in shading showed more significant injury in the initial phase. The increase in the glyphosate doses reduced the photochemical efficiency of the photosystem II (ФPSII), electron transport rate (ETR), photosynthetic rate, stomatal conductance, transpiration rate, and water use efficiency of D. insularis regardless of the cultivation environment. The light restriction increased the ФPSII in D. insularis at three days after applying the herbicide (DAH); at 6 DAH, the shaded plants showed a more pronounced reduction in ФPSII. D. insularis did not show root exudation of glyphosate, and shading did not influence this process.

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

BACKGROUND: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. METHODS: A retrospective, real-world analysis was performed on the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to subsequent treatment with ruxolitinib (n = 105) or the best available therapy (BAT; n = 272). Survival probabilities and rates of thrombosis, hemorrhage, acute myeloid leukemia, myelofibrosis, and second primary cancers were calculated according to treatment. To minimize biases in treatment allocation, all results were adjusted by a propensity score for receiving ruxolitinib or BAT. RESULTS: Patients receiving ruxolitinib had a significantly lower rate of arterial thrombosis than those on BAT (0.4% vs 2.3% per year; P = .03), and this persisted as a trend after adjustment for the propensity to have received the drug (incidence rate ratio, 0.18; 95% confidence interval, 0.02-1.3; P = .09). There were no significant differences in the rates of venous thrombosis (0.8% and 1.1% for ruxolitinib and BAT, respectively; P = .7) and major bleeding (0.8% and 0.9%, respectively; P = .9). Ruxolitinib exposure was not associated with a higher rate of second primary cancers, including all types of neoplasia, noncutaneous cancers, and nonmelanoma skin cancers. After a median follow-up of 3.5 years, there were no differences in survival or progression to acute leukemia or myelofibrosis between the 2 groups. CONCLUSIONS: The results suggest that ruxolitinib treatment for PV patients with resistance/intolerance to hydroxyurea may reduce the incidence of arterial thrombosis. LAY SUMMARY: Ruxolitinib is better than other available therapies in achieving hematocrit control and symptom relief in patients with polycythemia vera who are resistant/intolerant to hydroxyurea, but we still do not know whether ruxolitinib provides an additional benefit in preventing thrombosis or disease progression. We retrospectively studied the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to whether they subsequently received ruxolitinib (n = 105) or the best available therapy (n = 272). Our findings suggest that ruxolitinib could reduce the incidence of arterial thrombosis, but a disease-modifying effect could not be demonstrated for ruxolitinib in this patient population.

Light restriction associated with halosulfuron methyl application efficiently reduces the number and mass of tubers of Cyperus rotundus L.

This study evaluated the effect of light availability in the culture environment and the application of a post emergence herbicide, halosulfuron methyl, on the management of Cyperus rotundus. The experiment was arranged in a 2 × 6 factorial design; the first factor was two levels of light availability: photosynthetically active radiation at 1180.4 and 411.6 µmols m-2 s-1, and the second factor was halosulfuron methyl doses from 28.13 to 140.62 g ha-1. Photosynthetic efficiency, biomass allocation, accumulation of starch in tubers, and percentage control of C. rotundus were evaluated from 7 to 28 days after herbicide application. Doses greater than 70.30 g ha-1 of halosulfuron methyl were efficient to control C. rotundus, regardless of light availability. However, C. rotundus was managed faster under full sunlight than under shading. The efficiency of the photosystem, starch accumulation, and biomass formation decreased with increasing doses of halosulfuron methyl. In a shaded environment, a dose of 28.13 g ha-1 was sufficient to reduce 96.74% of the dry mass and 91.33% of the number of C. rotundus tubers. The decrease in light intensity associated with the use of halosulfuron methyl represents a promising practice for the control of C. rotundus.

Efecto de una intervención de alta programada sobre los reingresos de pacientes con insuficiencia cardíaca: estudio APRICA / Effect of a planned discharge intervention on readmissions of patients with heart failure APRICA study / Efeito de uma intervenção de alta planejada nas readmissões de pacientes com insuficiência cardíaca estudo APRICA

Introducción. La insuficiencia cardíaca (IC) es una enfermedad con alta incidencia, prevalencia y mortalidad. Es primera causa de hospitalización en mayores de 65 años y 25% de los pacientes que reingresan antes de 30 días. La implementación de varios planes de transición al alta han mostrado beneficios respecto a los reingresos, no habiendo datos al respecto en Uruguay. Se diseñó un estudio para analizar el efecto de un Plan de Alta Programada sobre los reingresos en pacientes internados con IC en un Hospital. Material y métodos. Estudio prospectivo, controlado y randomizado, incluyendo pacientes ingresados en servicios de medicina del Hospital de Clínicas Dr. Manuel Quintela con diagnóstico de IC. Criterios de exclusión: negativa a participar, discapacidad cognitiva, hospitalización d"24 horas o muerte en internación. Se randomizaron dos grupos (intervención y control) con seguimiento a 18 meses. En el grupo intervención se aplicó un plan de alta programada y en el grupo control el criterio de médico tratante. Se registraron reingresos, muerte y calidad de vida a los 3, 6, 9, 12 y 18 meses. Se consideró significativo un valor de p<0,05. Se utilizó la prueba de T- student para muestras independientes. Resultados. Se incluyeron 149 pacientes, 78 en el grupo intervención. Se registraron 19 (24,4%) reingresos en el grupo intervención y 38 (53,5%) en el grupo control (RR 1,85 [IC 1,337-2,583] p<0,05). Ocurrieron 6 muertes en el grupo intervención y 7 en el grupo control (RR: 1,024 [IC 0,926-1,32] p=0,640). La calidad de vida por Test de Minnesota fue 50,98; 49,71 y 49,07 en el grupo intervención a los 3, 6 y 18 meses, respectivamente, y 55,04; 55,32 y 54,91 en el grupo control, con un valor de p no significativo. Conclusiones. La implementación de un Plan de Alta Programada reduce de manera significativa los reingresos por IC. Dado que parece ser una herramienta costo/efectiva para el sistema de salud la misma podría tener un impacto beneficioso en la calidad asistencial del paciente con IC.

Background. Heart failure (HF) is a disease with a high incidence, prevalence and mortality. It is the first cause of hospitalization in people over 65 years and 25% of patients are readmitted within 30 days. The implementation of various discharge transition plans has shown benefits with respect to readmissions, and there is no data in this regard in Uruguay. A study was designed to analyze the effect of a Scheduled Discharge Plan on readmissions in hospitalized patients with HF. Material and methods. Prospective, controlled and randomized study, including patients admitted to the medical services of the Hospital de Clínicas Dr. Manuel Quintela with a diagnosis of HF. Exclusion criteria: refusal to participate, cognitive disability, hospitalization d"24 hours or death in hospital. Two groups (intervention and control) were randomized with 18-month follow-up. In the intervention group, a planned discharge plan was applied and the criterion of treating physician was applied in control. Readmissions, death and quality of life were recorded at 3, 6, 9, 12 and 18 months. A value of p <0.05 was considered significant. The student s T-test was used for independent samples. Results. 149 patients were included, 78 in the intervention group. There were 19 (24.4%) readmissions in the intervention group and 38 (53.5%) in the control group (RR 1.85 [CI 1.337-2.583] p <0.05). There were 6 deaths in the intervention group and 7 in the control group, (RR: 1,024 [CI 0.926-1.32] p = 0.640). The quality of life by Minnesota Test was 50.98; 49.71 and 49.07 in intervention at 3, 6 and 18 months respectively and 55.04; 55.32 and 54.91 in the control group, with a non-significant p value. Conclusions. The implementation of a Scheduled Discharge Plan significantly reduces readmissions for HF. Given that it appears to be a cost/effective tool for the health system, it could have a beneficial impact on the quality of care for patients with HF.

Introdução. A insuficiência cardíaca (IC) é uma doença com alta incidência, prevalência e mortalidade. É a primeira causa de hospitalização em pessoas com mais de 65 anos e 25% dos pacientes são readmitidos em 30 dias. A implementação de vários planos de transição de alta mostrou benefícios no que diz respeito às readmissões, e não há dados a esse respeito no Uruguai. Um estudo foi desenhado para analisar o efeito de um Plano de Alta Planejado nas readmissões em pacientes hospitalizados com IC. Material e métodos. Estudo prospectivo, controlado e randomizado, incluindo pacientes internados nos serviços médicos do Hospital de Clínicas Dr. Manuel Quintela com diagnóstico de IC. Critérios de exclusão: recusa em participar, deficiência cognitiva, internação d"24 horas ou óbito no hospital. Dois grupos foram randomizados (intervenção e controle) com seguimento de 18 meses. No grupo de intervenção, um plano de alta planejado foi aplicado e o critério de médico assistente foi aplicado no controle. Readmissões, óbito e qualidade de vida foram registrados aos 3, 6, 9, 12 e 18 meses. Um valor de p<0,05 foi considerado significativo. O teste T do aluno foi usado para amostras independentes. Resultados. Foram incluídos 149 pacientes, 78 no grupo de intervenção. Houve 19 (24,4%) readmissões no grupo de intervenção e 38 (53,5%) no grupo de controle (RR 1,85 [IC 1,337-2,583] p <0,05). Houve 6 mortes no grupo de intervenção e 7 no grupo controle, (RR: 1,024 [IC 0,926-1,32] p=0,640). A qualidade de vida pelo teste de Minnesotafoi de 50,98; 49,71 e 49,07 na intervenção em 3, 6 e 18 meses, respectivamente, e 55,04; 55,32 e 54,91 no grupo controle, com um valor de p não significativo. Conclusões. A implementação de um Plano de Descarga Planejado reduz significativamente as readmissões para IC. Visto que parece ser uma ferramenta econômica para o sistema de saúde, pode ter um impacto benéfico na qualidade do atendimento aos pacientes com IC.

Health care activity at the endocrinology and nutrition outpatient clinics of Castilla-La Mancha (the AACENCAM study).

INTRODUCTION: This study was promoted by Sociedad Castellano Manchega de Endocrinología, Nutrición y Diabetes to ascertain the characteristics of patients seen at the outpatient clinics of endocrinology and nutrition of the Castilla-La Mancha Health Authority and the case mix of diagnoses. PATIENTS AND METHODS: This was a retrospective, cross-sectional study of the activity of the endocrinology and nutrition outpatient clinics of public hospitals of Castile-La Mancha during 2018. All visits made on 10% of the working days were analyzed. Data collected comprised patient age and sex, whether a first or subsequent had been made, and whether this was face-to-face or not, and up to five diagnoses per visit. RESULTS: A total of 10,709 visits with a subsequent/first visit ratio of 3.4 were analyzed. Patient age was 52.1?±?18.2 years, and 67.1% were women. Type 2 diabetes mellitus, primary hypothyroidism, thyroid nodular disease, and obesity/overweight were the most common conditions recorded as first diagnosis, accounting for more than half of the total number of visits. Type 1 diabetes mellitus and thyroid cancer were the diagnoses in which the subsequent/first visit ratio was greater. Type 2 diabetes mellitus, obesity, and primary hypothyroidism accounted for almost half of the first visits. CONCLUSIONS: A wide variety of conditions were seen, some of which are among the most prevalent in the general population, while others are not so prevalent, but are complex and difficult to manage by other specialties. Improved knowledge and analysis of the data should allow for the identification of opportunities for improvement and for the implementation of specific actions.

Health care activity at the endocrinology and nutrition outpatient clinics of Castile-La Mancha (the AACENCAM study). / Actividad asistencial en las consultas de Endocrinología y Nutrición de Castilla-La Mancha (estudio AACENCAM).

INTRODUCTION: This study was promoted by Sociedad Castellano-Manchega de Endocrinología, Nutrición y Diabetes to ascertain the characteristics of patients seen at the outpatient clinics of endocrinology and nutrition of the Castilla-La Mancha Health Authority and the case mix of diagnoses. PATIENTS AND METHODS: This was a retrospective, cross-sectional study of the activity of the endocrinology and nutrition outpatient clinics of public hospitals of Castile-La Mancha during 2018. All visits made on 10% of the working days were analyzed. Data collected comprised patient age and sex, whether a first or subsequent had been made, and whether this was face-to-face or not, and up to five diagnoses per visit. RESULTS: A total of 10,709 visits with a subsequent/first visit ratio of 3.4 were analyzed. Patient age was 52.1 ± 18.2 years, and 67.1% were women. Type 2 diabetes mellitus, primary hypothyroidism, thyroid nodular disease, and obesity/overweight were the most common conditions recorded as first diagnosis, accounting for more than half of the total number of visits. Type 1 diabetes mellitus and thyroid cancer were the diagnoses in which the subsequent/first visit ratio was greater. Type 2 diabetes mellitus, obesity, and primary hypothyroidism accounted for almost half of the first visits. CONCLUSIONS: A wide variety of conditions were seen, some of which are among the most prevalent in the general population, while others are not so prevalent, but are complex and difficult to manage by other specialties. Improved knowledge and analysis of the data should allow for the identification of opportunities for improvement and for the implementation of specific actions.